The Gates Foundation will fund Novartis’ discovery and development of a gene therapy for sickle cell disease that is accessible for low- and middle-income countries.
List view / Grid view
Novartis Institutes for BioMedical Research (NIBR)
Preliminary research has revealed that some excipients used in common medications may interact with important human enzymes and receptors.
Kisqali receives breakthrough therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with HR+/HER2- advanced or metastatic breast cancer...